Letairis and Angioedema - a phase IV clinical study of FDA data

Summary:

Angioedema is reported as a side effect among people who take Letairis (ambrisentan), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Adcirca, and have Systemic sclerosis (scleroderma).

The phase IV clinical study analyzes which people have Angioedema when taking Letairis. It is created by eHealthMe based on reports of 93,991 people who have side effects when taking Letairis from the FDA, and is updated regularly.

What is Letairis?

Letairis has active ingredients of ambrisentan. It is often used in pulmonary hypertension. eHealthMe is studying from 94,041 Letairis users. Check the latest studies of Letairis.

What is Angioedema?

Angioedema (rapid swelling of the dermis) is found to be associated with 1,197 drugs and 2,089 conditions by eHealthMe. Check the latest studies of Angioedema.

On Jul, 09, 2026

93,991 people reported to have side effects when taking Letairis.
Among them, 70 people (0.07%) have Angioedema.

Among these 70 people:

How long have people been on Letairis when they have Angioedema? *

What is the gender of people who have Angioedema when taking Letairis? *

female: 72.46 %
male: 27.54 %

What is the age of people who have Angioedema when taking Letairis? *

What are other drugs people take besides Letairis? *

What are other side effects people have besides Angioedema? *

Dyspnea (difficult or laboured breathing): 20 people, 28.57%
Fluid Retention (an abnormal accumulation of fluid in the blood): 11 people, 15.71%
Headache (pain in head): 11 people, 15.71%
Chest Pain: 11 people, 15.71%
Oedema (fluid collection in tissue): 11 people, 15.71%
Lip Swelling: 9 people, 12.86%
Hypersensitivity: 7 people, 10.00%
Malaise (a feeling of general discomfort or uneasiness): 6 people, 8.57%
Swollen Tongue (swelling of tongue): 6 people, 8.57%
Swelling Face: 6 people, 8.57%

What are the existing conditions these people have? *

Systemic Sclerosis (Scleroderma) (an autoimmune or connective tissue disease. it is characterized by thickening of the skin): 3 people, 4.29%
High Blood Pressure: 2 people, 2.86%
Haemolytic Anaemia (anaemia due to haemolysis): 2 people, 2.86%
Depression: 2 people, 2.86%
Connective Tissue Disorder (any disease that has the connective tissues of the body): 2 people, 2.86%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 1 person, 1.43%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 1.43%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 1.43%
Gout (uric acid crystals building up in the body): 1 person, 1.43%
Drug Dependence: 1 person, 1.43%

* Approximation only. Some reports may have incomplete information.

Do you take Letairis and have Angioedema?

- Check whether Angioedema is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Letairis:

Letairis (94,041 reports)

Angioedema treatments and more:

Angioedema (44,989 reports)

Browse all side effects of Letairis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Angioedema:

Angioedema (1,197 drugs)

Browse all the conditions that are associated with Angioedema:

Angioedema (2,089 conditions)

Related publications that referenced our studies

Banaga, Y., Mohmmed, K., Mustafa, H., & Barrett, J, "Angioedema 2 months after Administration of Rivaroxaban (Xarelto)", J Clin Case Rep, 2014 Jan .
Banaga, Y., Mohmmed, K., Mustafa, H., & Barrett, J, "Angioedema 2 months after Administration of Rivaroxaban (Xarelto)", J Clin Case Rep, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on ambrisentan (the active ingredients of Letairis) and Letairis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.